Abstract

Nucleic-acid aptamers have the molecular recognition properties of antibodies, and can be isolated robotically for high-throughput applications in diagnostics, research and therapeutics. Unlike antibodies, however, they can be chemically derivatized easily to extend their lifetimes in biological fluids and their bioavailability in animals. The first aptamer-based clinical drugs have recently entered service. Meanwhile, active research programmes have identified a wide range of anti-viral aptamers that could form the basis for future therapeutics.

Author affiliations

1. Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, UK.

Correspondence to: Peter G. Stockley¹ Email: stockley@bmb.leeds.ac.uk

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.